lancet-header

Preprints with The Lancet is part of SSRN´s First Look, a place where journals identify content of interest prior to publication. Authors have opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early stage research papers that have not been peer-reviewed. The findings should not be used for clinical or public health decision making and should not be presented to a lay audience without highlighting that they are preliminary and have not been peer-reviewed. For more information on this collaboration, see the comments published in The Lancet about the trial period, and our decision to make this a permanent offering, or visit The Lancet´s FAQ page, and for any feedback please contact preprints@lancet.com.

The Inhibition of IL-2/IL-2R Gives Rise to CD8+T Cell and Lymphocyte Decrease Through JAK1-STAT5 in Critical Patients with COVID-19 Pneumonia

20 Pages Posted: 20 Apr 2020

See all articles by Hongbo Shi

Hongbo Shi

Capital Medical University - Beijing Institute of Hepatology; Beijing Engineering Research Center for Precision Medicine and Transformation of Hepatitis and Liver Cancer

Wenjing Wang

Capital Medical University - Beijing Institute of Hepatology; Beijing Engineering Research Center for Precision Medicine and Transformation of Hepatitis and Liver Cancer

Jiming Yin

Capital Medical University - Beijing Institute of Hepatology; Beijing Engineering Research Center for Precision Medicine and Transformation of Hepatitis and Liver Cancer

Yabo Ouyang

Capital Medical University - Beijing Institute of Hepatology; Beijing Engineering Research Center for Precision Medicine and Transformation of Hepatitis and Liver Cancer

Lijun Pang

Capital Medical University - Beijing Institute of Hepatology; Beijing Engineering Research Center for Precision Medicine and Transformation of Hepatitis and Liver Cancer

Yingmei Feng

Capital Medical University - Beijing Institute of Hepatology; Beijing Engineering Research Center for Precision Medicine and Transformation of Hepatitis and Liver Cancer

Luxin Qiao

Capital Medical University - Beijing Institute of Hepatology; Beijing Engineering Research Center for Precision Medicine and Transformation of Hepatitis and Liver Cancer

Xianghua Guo

Capital Medical University - Beijing Institute of Hepatology; Beijing Engineering Research Center for Precision Medicine and Transformation of Hepatitis and Liver Cancer

Honglin Shi

Capital Medical University - Beijing Institute of Hepatology; Beijing Engineering Research Center for Precision Medicine and Transformation of Hepatitis and Liver Cancer

Ronghua Jin

Capital Medical University - Beijing Institute of Hepatology; Beijing Engineering Research Center for Precision Medicine and Transformation of Hepatitis and Liver Cancer

Dexi Chen

Capital Medical University - Beijing Institute of Hepatology; Beijing Engineering Research Center for Precision Medicine and Transformation of Hepatitis and Liver Cancer

More...

Abstract

Background: Although most patients with COVID-19 pneumonia have a good prognosis, some patients develop to severe or critical cases, and the mortality of critical cases was up to 61.5%. However, specific information and molecular mechanism about critical patients with COVID-19 was poorly understood.

Methods: A total of 54 patients were enrolled and divided into three groups, among which 34 were common type, 14 were severe type, and 6 were critical type. The constitution of peripheral blood mononuclear cells (PBMC) in patients was analyzed by CyTOF. The profile of cytokines was performed in plasma of patients using Luminex. The IL-2 signaling pathway was investigated in the PBMC of patients by qRT-PCR.

Results: The lymphocytes count and percentage were significantly decreased in critical patients compared to common and severe patients with COVID-19 pneumonia. CD8+T cells were remarkably decreased in critical patients compared to common, severe patients and normal controls, which suggested the decrease of lymphocytes may be attributed to the reduction of T cells in critical patients. The expression of IL-2R, JAK1, and STAT5 decreased in immune cells of common, severe, and critical patients, but IL-2 level was elevated in severe patients and decreased in critical patients with COVID-19 pneumonia.

Conclusion: The decrease of CD8+T cells in critical patients with COVID-19 pneumonia may be related to the IL-2 signaling pathway. The inhibition of IL-2/IL-2R gives rise to CD8+T cell and lymphocyte decrease through JAK1-STAT5 in critical patients with COVID-19 pneumonia.

Funding Statement: This study was financially supported by COVID-19 Key Technology Research and Development Funding of Beijing Hospital Authority; The National Natural Science Foundation of China (81672026); National Science and Technology Major Project of China (2018ZX10302205-005).

Declaration of Interests: The authors confirm that there are no conflicts of interest.

Ethics Approval Statement: The study was approved by the Ethics Committee of Beijing Youan Hospital, Capital Medical University, China.

Keywords: Corona Virus Disease 2019 (COVID-19), Critical patient, Interleukin 2 (IL-2), IL-2 receptor, CD8+T cell

Suggested Citation

Shi, Hongbo and Wang, Wenjing and Yin, Jiming and Ouyang, Yabo and Pang, Lijun and Feng, Yingmei and Qiao, Luxin and Guo, Xianghua and Shi, Honglin and Jin, Ronghua and Chen, Dexi, The Inhibition of IL-2/IL-2R Gives Rise to CD8+T Cell and Lymphocyte Decrease Through JAK1-STAT5 in Critical Patients with COVID-19 Pneumonia (4/3/2020). Available at SSRN: https://ssrn.com/abstract=3571510 or http://dx.doi.org/10.2139/ssrn.3571510

Hongbo Shi

Capital Medical University - Beijing Institute of Hepatology

Beijing, 100069
China

Beijing Engineering Research Center for Precision Medicine and Transformation of Hepatitis and Liver Cancer

Beijing
China

Wenjing Wang

Capital Medical University - Beijing Institute of Hepatology

Beijing, 100069
China

Beijing Engineering Research Center for Precision Medicine and Transformation of Hepatitis and Liver Cancer

Beijing
China

Jiming Yin

Capital Medical University - Beijing Institute of Hepatology

Beijing, 100069
China

Beijing Engineering Research Center for Precision Medicine and Transformation of Hepatitis and Liver Cancer

Beijing
China

Yabo Ouyang

Capital Medical University - Beijing Institute of Hepatology

Beijing, 100069
China

Beijing Engineering Research Center for Precision Medicine and Transformation of Hepatitis and Liver Cancer

Beijing
China

Lijun Pang

Capital Medical University - Beijing Institute of Hepatology

Beijing, 100069
China

Beijing Engineering Research Center for Precision Medicine and Transformation of Hepatitis and Liver Cancer

Beijing
China

Yingmei Feng

Capital Medical University - Beijing Institute of Hepatology ( email )

Beijing, 100069
China

Beijing Engineering Research Center for Precision Medicine and Transformation of Hepatitis and Liver Cancer ( email )

Beijing
China

Luxin Qiao

Capital Medical University - Beijing Institute of Hepatology

Beijing, 100069
China

Beijing Engineering Research Center for Precision Medicine and Transformation of Hepatitis and Liver Cancer

Beijing
China

Xianghua Guo

Capital Medical University - Beijing Institute of Hepatology

Beijing, 100069
China

Beijing Engineering Research Center for Precision Medicine and Transformation of Hepatitis and Liver Cancer

Beijing
China

Honglin Shi

Capital Medical University - Beijing Institute of Hepatology

Beijing, 100069
China

Beijing Engineering Research Center for Precision Medicine and Transformation of Hepatitis and Liver Cancer

Beijing
China

Ronghua Jin

Capital Medical University - Beijing Institute of Hepatology ( email )

Beijing, 100069
China

Beijing Engineering Research Center for Precision Medicine and Transformation of Hepatitis and Liver Cancer ( email )

Beijing
China

Dexi Chen (Contact Author)

Capital Medical University - Beijing Institute of Hepatology ( email )

Beijing, 100069
China

Beijing Engineering Research Center for Precision Medicine and Transformation of Hepatitis and Liver Cancer ( email )

Beijing
China

Click here to go to TheLancet.com

Paper statistics

Abstract Views
1,701
Downloads
47
PlumX Metrics